Risks and benefits of β-receptor blockers for pregnancy hypertension: overview of the randomized trials
- 1 January 2000
- journal article
- research article
- Published by Elsevier BV in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 88 (1), 15-26
- https://doi.org/10.1016/s0301-2115(99)00113-x
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Labetalol vs. methyldopa in the treatment of pregnancy-induced hypertensionInternational Journal of Gynecology & Obstetrics, 1995
- Review papers : The statistical basis of meta-analysisStatistical Methods in Medical Research, 1993
- Neonatal adaptation in hypertensive pregnancy — A study of labetalol vs hydralazine treatmentjpme, 1993
- Comparative Risk-Benefit Assessment of Drugs Used in the Management of Hypertension in PregnancyDrug Safety, 1992
- Antihypertensive Therapy in the Management of Hypertension in Pregnancy - A Clinical Double-Blind Study of PindololClinical and Experimental Hypertension. Part B: Hypertension in Pregnancy, 1992
- Maternal Obstetric Outcome Measures in A Randomised Controlled Study of Labetalol in the Treatment of Hypertension in PregnancyClinical and Experimental Hypertension. Part B: Hypertension in Pregnancy, 1991
- Management of pregnancy‐induced hypertension with pindolol‐comparative study with methyldopaInternational Journal of Gynecology & Obstetrics, 1986
- A Prospective Controlled trial of Metoprolol-Hydralazine Treatment in Hypertension during PregnancyActa Obstetricia et Gynecologica Scandinavica, 1985
- Intravenous Labetalol and Intravenous Dihydralazine in Severe Hypertension in PregnancyClinical and Experimental Hypertension. Part B: Hypertension in Pregnancy, 1982
- Comparison of the Alpha and Beta Blocking Drug, Labetalol, and Methyl Dopa in the Treatment of Moderate and Severe Pregnancy-Induced HypertensionClinical and Experimental Hypertension, 1980